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Matrix metalloproteinases (MMPs) and cyclooxygenase-2 (COX-2) are expressed in both sporadic and familial adenomatous colonic
polyps and tumours and have been independently shown to play causal roles in intestinal tumour formation in mouse models of
colon cancer. The apparent roles of these enzymes in intestinal tumorigenesis led us to examine, in the Min mouse model of colon
cancer, if selective COX-2 and MMP inhibitors provide additive or synergistic therapeutic benefits in intestinal tumour prevention.
The broad-spectrum MMP inhibitor (A-177430; MMPI) and the selective COX-2 inhibitor (A-285969; COX-2I) both showed dose-
dependent inhibition of the number of adenomas in Min mice. Using suboptimal doses, the MMPI reduced tumour multiplicity by
32%, the COX-2I by 48% and, both agents in combination resulted in a 67% decrease compared to control demonstrating a
cooperative effect on intestinal tumorigenesis. Apoptosis, proliferation, and angiogenesis were assayed in tumors from each treatment
group. These agents in combination allowed for a lowered dosage to be administered to achieve significant biological effects.
Clinically, this could potentially reduce side effects associated with currently used MMP and COX-2 inhibitors. Together, these
compounds could represent an easily tolerated chemopreventive approach.
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Colon cancer is the third largest cause of cancer-related deaths in
both men and women in the US. Sporadic colorectal cancer is a
multistep process involving a number of genetic and epigenetic
changes (Fearon and Vogelstein, 1990; Kinzler and Vogelstein,
1996), while familial forms such as familial adenomatous polyposis
(FAP) and hereditary nonpolyposis colorectal cancer (HNPCC)
have been shown to be caused by mutations in the tumour
suppressor adenomatous polyposis coli (APC) and mismatch
repair (MMR) genes, respectively. There are multiple stages and
many years involved in the progression from benign colon polyp
to invasive carcinoma and metastatic disease. In addition to efforts
to improve therapy for colorectal cancer, the detection of early-
stage lesions by colonoscopy provides the opportunity to develop
novel chemopreventive approaches to this disease.
Inhibitors of cyclooxygenase (COX, prostaglandin H synthase),
the enzyme that catalyses the conversion of arachidonic acid to
prostaglandin, have been utilised as chemopreventive agents for
colorectal cancer. There are two forms of the COX enzyme; COX-1
is expressed ubiquitously while COX-2 expression is induced in
response to a number of different stimuli including cytokines,
growth factors, oncogenes, serum, and tumour promoters (Kujubu
et al, 1991; O’Banion et al, 1991). COX-2 is expressed in 85–90% of
human colorectal adenocarcinomas (Eberhart et al, 1994; Kargman
et al, 1995; Sano et al, 1995). Initial studies of COX and colorectal
tumours came about after epidemiological studies linked non-
steroidal anti-inflammatory drug (NSAID) intake with reduced
risk for developing colorectal tumours (Thun et al, 2002). Clinical
trials in FAP patients with NSAIDs showed that their use results in
significant reduction in both the number and size of the polyps
(Hawk et al, 1999). These studies also demonstrated that NSAIDs
had adverse side effects of bleeding and ulceration, which was
most likely because of inhibition of gastric prostaglandin
production by COX-1.
A number of animal models have been used to determine the
effectiveness of COX inhibition in the treatment and prevention of
colorectal cancer. Among these is the multiple intestinal neoplasia
(Min) mouse (Williams et al, 1996), which carries an ethyl-
nitrosourea-induced germline mutation at codon 850 in exon 15 of
the APC gene that results in a truncated protein (Su et al, 1992).
Within the context of the C57Bl/6 genetic background, 100% of
mice with the Min mutation develop adenomas throughout the
intestinal tract (Moser et al, 1990). NSAIDs such as piroxicam,
indomethacin, and sulindac were all effective in preventing
intestinal tumorigenesis in this model (Beazer-Barclay et al,
1996; Gann et al, 1993; Marnett, 1995; Reddy, 1987; Wargovich
et al, 1995; Jacoby et al, 1996). Furthermore, mice null for COX-2
in an APC mutant background (APCD716) develop 86% fewer
tumours than mice with COX-2 expression (Oshima et al, 1996).
In addition to altered expression of COX-2, members of the
matrix metalloproteinase (MMP) family are induced in colon
cancer (McDonnell et al, 1991). The MMPs are a growing family of
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senzymes, currently consisting of more than 20 mammalian family
members, which have been shown to play a role in tumours
originating in several different organs (for review see Nelson et al,
2000). MMPs are zinc-dependent enzymes capable of degrading
extracellular matrix components. A number of different MMPs
may be important in intestinal tumour formation as human
tumours have been shown to express interstitial collagenase
(MMP-1), gelatinase A (MMP-2), stromelysin 1 (MMP-3), matri-
lysin (MMP-7), gelatinase B (MMP-9), and stromelysin 3 (MMP-
11) (Newell et al, 1994; Nelson et al, 2000). MMP-7, an epithelial
specific MMP, is expressed focally in 50% of benign colonic
adenomas and overexpressed in 85% of human malignant
colorectal tumours (Newell et al, 1994). Additionally, MMP-7
is overexpressed in 90% of adenomas from patients with FAP
(Takeuchi et al, 1997).
The Min mouse model of gastrointestinal tumorigenesis has also
been used to indicate that MMPs play causative roles in tumour
formation. We have previously shown that 70 – 90% of Min
adenomas express MMP-7 in the neoplastic epithelium (Wilson
et al, 1997; Shattuck-Brandt et al, 1999) and that Min mice null for
MMP-7 have 58% fewer tumours than Min mice with wild-type
MMP-7 (Wilson et al, 1997). Tumour multiplicity in Min mice
treated with a broad-spectrum MMP inhibitor, batimistat (BB94),
was decreased by 48% as compared to vehicle-treated mice (Goss
et al, 1998). In addition to MMP-7 expression, 60–65% of Min
adenomas express MMP-2 and MMP-10 (stromelysin-2) and 50%
express MMP-3 and MMP-13 (collagenase) with expression limited
to the stroma surrounding the adenoma (Wilson et al, 1997).
The similarity in tissue expression of both MMP-7 and COX-2
and the apparent roles that these enzymes have in intestinal
tumorigenesis suggested that their expression may be coregulated
in polyps of the Min mouse. Although both enzymes were
expressed at high levels in the Min adenomas, in situ and
immunohistochemistry localised MMP-7 specifically to the neo-
plastic epithelial cells, while COX-2 was localised to the superficial
stroma within the adenoma (Shattuck-Brandt et al, 1999).
Recently, COX-2 has been shown to be expressed in the polyp-
associated fibroblasts and endothelial cells of intestinal polyps
from ApcD716 mice (Sonoshita et al, 2002). Additionally, a high
percentage of human colorectal tumours expressed both MMP-7
and COX-2, although, the levels and localisation of MMP-7 and
COX-2 expression within the tumours did not correlate (Shattuck-
Brandt et al, 1999). It is also important to note that neither COX-2
nor MMP-7 is expressed in normal intestinal epithelium but
instead is upregulated in the tumors making inhibition of both
of these enzymes an ideal therapeutic target. These results
suggested that MMP-7 and COX-2 are not coregulated and that
there is no direct relation between the expression of COX-2 and the
expression of MMP-7.
Since COX-2 and MMP-7 are not coregulated and are unlikely to
be part of the same signal-transduction pathway, we hypothesised
that combination therapy with selective COX-2 and MMP
inhibitors may provide additive or synergistic therapeutic benefits
in the Min mouse model. We report that the administration of a
broad-spectrum MMP inhibitor (A-177430) and a selective COX-2
inhibitor (A-285969) to Min mice significantly suppresses
intestinal tumorigenesis, and that administration of both the
MMP inhibitor (MMPI) and the COX-2 inhibitor (COX-2I) in
combination further reduces intestinal tumorigenesis to a level
that is greater than either compound individually.
MATERIALS AND METHODS
Animals
C57Bl/6-Min (Min) mice (Jackson Laboratory, Bar Harbor, ME,
USA) were maintained as previously described with littermates
housed under identical conditions in microisolator cages (Wilson
et al, 1997). Pups were weaned at 3 weeks of age and maintained
ad libitum on diet 5015 (Purina Mills Inc. LabDiet, Richmond IN,
USA). Analysis of the Min allele was performed as described using
a PCR assay (Whitehead and Joseph, 1994). Mice were weighed
twice weekly and gained weight at normal rate. All animal
protocols were approved by Vanderbilt University Animal Care
and Use Committee.
Therapeutic agents
A-177430 and A-285969 were synthesised at Abbott Laboratories
(Abbott Park, IL, USA; Figure 1). Single-agent study: mice were
administered A-177430 at a dose of 100mgkg
 1 (200mgkg
 1day
 1,
n¼6) suspended in 0.2% hydroxypropylmethylcellulose (HPMC),
A-285969 at 40mgkg
 1 (80mgkg
 1day
 1, n¼5) suspended in
HPMC. Sulindac was given as a positive control for tumour inhi-
bition and was given at a dose of 1.875mgkg
 1 (3.75mgkg
 1day
 1,
n¼6) while HPMC-injected mice were used as control (n¼3).
Combination study: mice were administered A-177430 at a dose of
30mgkg
 1 (60mgkg
 1day
 1, n¼6) suspended in 0.2% HPMC, A-
285969 at 20mgkg
 1 (40mgkg
 1day
 1, n¼5) suspended in
HPMC, both A-177430 and A-285969 at the doses used in single
compound treatment (n¼6), or vehicle (HPMC) alone (n¼5). All
compounds were administered by intraperitoneal (i.p.) injection
twice daily for 45 days beginning at 5 weeks of age. The twice daily
dose of 40 and 20mgkg
 1 of A-285969 was chosen because pilot
studies have shown A-285969 to be active in a mouse cornea model
of angiogenesis at 50mgkg
 1 (Leal J and Bell R, unpublished data)
and because doses of 20mgkg
 1 have shown to be safe on the
gastrointestinal tract of dogs (Bell R in preparation). The twice daily
dose of 100 and 30mgkg
 1 of A-177430 was chosen because these
doses have been previously shown to be effective in inhibiting
tumour growth of the MatLyLu prostate cancer cell line in rats
(Rabbani et al, 2000). Mouse pharmacokinetics give a half-life of less
than 4h for both the MMPI and COX-2I indicating the need for
twice daily dosing. No clinical data are available regarding possible
toxicities of either of these compounds in humans.
Analysis of tumour formation
For analysis of intestinal tumours, animals were killed by CO2
asphyxiation. Intestinal tissue was fixed overnight in 4%
paraformaldehyde (Fluka Chemika-Biochemica, Switzerland) in
1 PBS and transferred to 70% ethanol for storage at 41C.
Intestines were cut longitudinally and tumours were analysed
under a dissecting microscope at  10 magnification. Tumour
sample identifications were masked and the number, diameter, and
distribution of tumours were recorded.
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Figure 1 Structure of MMPI A-177430 (A) and COX-2I A-285969 (B).
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sImmunohistochemistry
Tumours were dissected out of the fixed intestines and embedded
in paraffin. Sections (5mm) were cut and mounted on Superfrost
Plus slides (Fisher Scientific, Pittsburgh, PA, USA). Slides were
stained for apoptosis using the ApopTag Kit (Intergen, Purchase,
NY, USA) according to the manufacturer’s instructions. Nuclei
were visualised by counterstaining with Contrast Green. Apoptosis
results were quantified by counting the number of positively
stained tumour-associated nuclei per 1000 total tumour-associated
nuclei. Results are expressed as percent positively stained nuclei.
Analysis of cell proliferation was performed with a monoclonal
mouse anti-Ki67 antibody (Novocastra Laboratories Ltd., New-
castle upon Tyne, UK). Antigen retrieval was performed with
Target Retrieval solution (DAKO Laboratories, Carpinteria, CA,
USA) according to the manufacturer’s instructions. Negative
controls consisted of sections that were incubated in control IgG
antibody. Endogenous peroxidase and biotin were quenched with
0.03% hydrogen peroxide and Biotin Blocking System (DAKO
Laboratories, Carpinteria, CA, USA), respectively. A primary
antisera dilution of 1:50 was prepared using the Animal Research
Kit/Peroxidase (DAKO Laboratories, Carpinteria, CA, USA) bio-
tinylation and blocking reagents and slides were incubated for 6h.
Diaminobenzidine (DAB) plus was used to produce localised,
visible staining followed by a haematoxylin counterstain.
Immunohistochemistry results were quantified by counting the
number of positive tumour-associated nuclei out of the total
number of tumour-associated nuclei with a minimum of 600 nuclei
analysed for each tumour. Results are expressed as percent of
nuclei staining positive.
Analysis of angiogenesis was performed with a rabbit anti-
human Von Willebrand factor (VWF) antibody obtained from
DAKO Laboratories. Endogenous peroxidases were quenched with
0.6% hydrogen peroxide. Antigen retrieval was accomplished by
proteinase K digestion in a solution of 4% proteinase K for 30min
at room temperature. Sections were incubated in control IgG
antibody (negative control) or rabbit anti-VWF antibody (1:2000)
overnight at 41C and developed with the Vectastain ABC kit from
Vector Laboratories (Burlingame, CA, USA) according to the
manufacturer’s instructions. Immunohistochemistry staining for
VWF was quantified using Zeiss Image (Carl Zeiss, Inc., Thorn-
wood, NY, USA) and results are expressed as percent of total
tumour area stained.
Statistics
All values were determined using the StatView program (SAS
Institute Inc, Cary, NC, USA). A value was determined to be
statistically significant if the P-value is less than 0.05 as determined
with the nonparametric Mann–Whitney test.
RESULTS
Effect of therapeutic agents on tumour multiplicity
The MMP inhibitor A-177430 (referred to as MMPI) is a previously
described broad-spectrum MMP inhibitor (Sheppard et al, 1998),
which contains a hydroxamic acid moiety that chelates the MMP
active site zinc ion and inhibits enzymatic activity with IC50 values
of 2–6nM for MMPs -1, -2, -3, -7, and -9. This MMPI has been used
successfully at 100mgkg
 1 to inhibit tumour growth and meta-
stasis in rats inoculated with MatLyLu rat prostate cancer cells
(Rabbani et al, 2000). A-285969 (referred to as COX-2I) is a selec-
tive COX-2 inhibitor that shows 60-fold selectivity against COX-2
vs COX-1 in human whole-blood assays. It also potently inhibits
COX-2-driven prostaglandin formation in rodents (oral ED50
0.7mgkg
 1), prostaglandin-driven inflammation (ED50¼1.0mgkg
 1)
in adjuvant arthritis in rats, and angiogenesis in a mouse cornea
model of angiogenesis (50mgkg
 1) (R Bell, in preparation).
The ability of these compounds to alter tumour multiplicity was
examined using 5 to 6-week-old Min mice. In the single-agent
study, mice were treated for 45 days with vehicle (HPMC), MMPI
at 100mgkg
 1 (200mgkg
 1day
 1) or COX-2I at 40mgkg
 1
(80mgkg
 1day
 1) as indicated in Materials and Methods. The
NSAID sulindac was used as a positive control. Both the MMPI and
the COX-2I reduced tumour multiplicity by 69% (5.672.5) and
64% (6.471.5), respectively, compared to vehicle-treated controls
(1872). Sulindac was less effective than either of the MMPI or the
COX-2I in this experiment (Figure 2A).
To determine if there is a cooperative effect of inhibiting
both the MMPs and COX-2 pathways, the experiment was repeated
using lower doses of the MMPI and COX-2I separately and
in combination. Lower doses of the two compounds were used
than in the single-agent study to ensure if the two inhibitors
cooperated, additive or synergistic effects could be observed. Min
mice were treated with vehicle (HPMC) or suboptimal doses of
MMPI at 30mgkg
 1 (60mgkg
 1day
 1), COX-2I at 20mgkg
 1
(40mgkg
 1day
 1) or both MMPI and COX-2I at the same doses
used in the individual treatments as indicated in Materials and
Methods. Tumour multiplicity was reduced in MMPI-treated mice
by 32% (9.071.7; P¼0.0367) and by 48% (6.870.84; P¼0.0090)
in COX-2I-treated mice as compared to vehicle-treated mice
(13.272.8) as shown in Figure 2B. Treatment with a combination
of MMPI and COX-2I decreased tumour multiplicity by 67%
(4.370.82; P¼0.0062) as compared with vehicle-treated mice.
Additionally, the reduction in tumour number in combination-
treated mice was significantly greater than mice treated with either
compound individually (Figure 2B). These results most closely
represent an additive effect for these drug interactions as
determined by the algebraic method (Berenbaum, 1977). The
average tumour diameter was not affected by treatment with any of
the therapeutic agents (Figure 2C). No weight loss or alterations in
feeding were noted in mice treated with either of the doses of
MMPI or COX-2I or the combination of the two compounds (data
not shown). No gastrointestinal ulcers were noted by gross analysis
of intestines from any of the treatment animals.
Effect of therapeutic agents on tumour apoptosis
Intestinal tumour sections were assessed for DNA fragmentation
to determine if an increased rate of apoptosis may be a mechanism
by which MMPI and COX-2I decreased Min tumour multiplicity.
Tumours from mice treated with MMPI had a 3.9-fold increased
apoptotic index compared with tumours from vehicle-treated
mice, with 1.2570.50% apoptotic nuclei in tumours from vehicle-
treated mice to 4.8372.87% apoptotic nuclei in tumours from
MMPI-treated mice (Figure 3A; P¼0.0012). Similarly, tumours
from mice treated with COX-2I exhibited an increased apoptotic
index of four-fold as compared with vehicle-treated mice (1.257
0.50% apoptotic nuclei in vehicle mice to 4.9172.47% apoptotic
nuclei in mice treated with COX-2I, Figure 3A; P¼0.0018).
Additionally, tumours from mice treated with the combination
of the MMP and COX-2 inhibitors had a 2.5-fold increase in the
apoptotic index (3.2270.97%; P¼0.0090) compared to tumours
from mice treated with vehicle; however, there was no significant
increase in the rate of apoptosis over treatment with either MMPI
or COX-2I alone (Figure 3A). Representative staining is shown in
Figure 3B.
Effect of therapeutic agents on tumour proliferation
Tumour sections were stained for Ki67 to determine if MMPI and
COX-2I alone or in combination altered the level of cell
proliferation. Ki67 is a nuclear antigen expressed in proliferating
cells during late G1, S, M, and G2 stages of the cell cycle. Min
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stumours treated with MMPI did not exhibit a statistically
significant decrease in cell proliferation compared to tumours
from control-treated animals (25.975.8% and 30.1711.4%,
respectively, Figure 4A). Tumours from Min mice treated with
COX-2I, however, exhibited significantly reduced levels of cell
proliferation from 30.1711.4%, in vehicle-treated mice to
13.876.9% (Figure 4A; P¼0.0251). Tumours from Min mice
treated with the combination MMPI and COX-2I did not exhibit a
significantly different rate of proliferation than tumours from mice
treated with the COX-2I alone (Figure 4A). Representative staining
is shown in Figure 4B.
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Figure 3 Tumours from Min mice treated with MMPI or COX-2I have
increased levels of apoptosis in comparison with vehicle-treated mice.
Intestinal tumour sections were stained for apoptosis using the ApopTag kit
and number of positive nuclei and total tumour-associated nuclei were
counted as described in Materials and Methods. (A) A total of 1000 nuclei
were counted per tumour. Results are represented as percent nuclei
staining positive. Each bar is representative of total number of tumours
scored for each group where vehicle n¼11, MMPI n¼10, COX-2I n¼10,
and combination n¼6. Statistical differences were calculated as described
in Materials and Methods by comparing vehicle and treated groups.
*P¼0.0012, **P¼0.0018, ***P¼0.009. (B) Representative staining for
apoptosis from each treatment group. Apoptotic nuclei are stained brown
and contrast green is used to visualize total nuclei.
3
Figure 2 MMPI (A-177430) and COX-2I (A-285969) cooperate to
reduce tumour multiplicity in Min mice. Single-dose study (A) involved
treatment of Min mice at 5–6 weeks for 45 days with twice daily i.p.
injections of vehicle (HPMC, n¼3), a broad-spectrum MMPI (A-177430,
n¼6), a COX-2I (A-285969, n¼5), or an NSAID (sulindac, n¼6) at the
doses indicated. *Denotes statistically significant difference between
individual treatment groups and the vehicle-treated group. Combination
study (B) repeated the above regimen using suboptimal doses alone and in
combination as indicated. Each bar is representative of the total number of
mice in the experiment where vehicle n¼5, COX-2I n¼5, MMPI n¼6,
and combination n¼6. Statistical differences were calculated as described
in Materials and Methods by comparing vehicle and treated groups
*P¼0.0367, **P¼0.009, ***P¼0.0062 or the combination-treated
group and individual treatment groups.
zP¼0.0062. Tumour size (C)
was determined as described in Materials and Methods.
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sEffect of therapeutic agents on angiogenesis
Intestinal tumour sections from each treatment group were stained
for VWF to determine if MMPI or COX-2I used alone or in
combination could alter angiogenesis. Staining was quantified
using Zeiss Image and is presented as percent of total tumour area.
No significant difference in staining for VWF was observed in
tumours from mice treated with MMPI or COX-2I alone
(Figure 5A). However, treatment with MMPI and COX-2I in
combination significantly reduced the amount of VWF staining
when compared to vehicle (P¼0.0005) or MMPI (P¼0.0009) and
COX-2I (P¼0.0031) used individually (Figure 5A). Representative
staining is shown in Figure 5B.
DISCUSSION
The purpose of this study was to determine if the combination of a
broad spectrum MMP inhibitor (A-177430) and a selective COX-2
inhibitor (A-285969) could cooperate to reduce intestinal tumour
formation in Min mice. We have previously shown that MMPs and
COX-2 are expressed in a high percentage of Min tumours (Wilson
et al, 1997; Shattuck-Brandt et al, 1999). It has also been shown
that elimination of MMPs or COX-2 by either genetic strategies or
with inhibitors results in a decrease in the number of tumours
formed in mice with altered APC function (Wilson et al, 1997; Goss
et al, 1998). We hypothesised that treatment of intestinal cancer
with both MMP inhibitors and COX-2 inhibitors could result in a
further decrease in tumour number and/or size as compared to
treatment with the individual inhibitors.
Both the MMPI and the COX-2I decreased Min tumour
multiplicity in a dose-dependent manner. These results are
consistent with previously published data using structurally
distinct MMP and COX-2 inhibitors (Beazer-Barclay et al, 1996;
Jacoby et al, 1996; Oshima et al, 1996). These data provide further
support to the contention that these enzymes contribute to
intestinal tumour progression and represent valid chemothera-
peutic targets for colon cancer. No effect on tumour diameter was
observed in any of the treatment groups at any of the doses tested.
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Figure 4 Cell proliferation is significantly inhibited in tumours from Min
mice treated with COX-2I but not with MMPI. Immunohistochemistry was
performed with a Novocastra anti-human Ki67 antibody as described in
Materials and Methods. (A) A minimum of 600 total tumour-associated
nuclei were counted and results are represented as percent of nuclei
staining positive out of total tumour-associated nuclei. Each bar is
representative of total number of tumours scored for each group where
vehicle n¼7, COX-2I n¼5, MMPI n¼13, and combination n¼5.
Statistical differences were calculated as described in Materials and
Methods by comparing vehicle and treated groups. **P¼0.0185,
***P¼0.0058. (B) Representative examples of Ki67 staining for each
treatment group. Proliferative nuclei are stained brown and all nuclei are
counterstained blue with hematoxylin.
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Figure 5 Combination treatment with both MMPI and COX-2I inhibits
angiogenesis in Min intestinal tumours, while single-agent therapy does not
alter angiogenesis. Immunohistochemistry for Von Willibrand Factor (VWF)
was performed with a DAKO anti-VWF antibody as described in Materials
and Methods. (A) Quantification of immunostaining was performed using
Zeiss Image. Each bar is representative of the total number of tumours
scored for each group where vehicle n¼9, MMPI n¼8, COX-2I n¼6, and
combination n¼6. Statistical differences were calculated as described in
Materials and Methods by comparing vehicle-and combination-treated
group. ***P¼0.0005,
zMMPI and combination P¼0.0009 and COX-2I
and combination P¼0.0031. (B) Representative examples of VWF
immunohistochemistry for each treatment group. VWF-positive vessels
are stained brown and all nuclei are counterstained blue with haematoxylin.
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MMPs have been inhibited using a structurally distinct MMPI and
with tissue inhibitors of metalloproteinases (TIMPs), endogenous
inhibitors of MMPs (Goss et al, 1998). It is unclear if longer
treatment may have resulted in observable differences in tumour
size. The novel aspect of these studies is the observation that
combination treatment of the Min mice with both MMP and COX-
2 inhibitors resulted in an additive decrease in the average tumour
number.
The mechanism of inhibition of tumour number was investi-
gated by assaying for tumour apoptosis, proliferation, and
angiogenesis. The MMPI alone raised the level of tumour cell
apoptosis, but did not significantly affect proliferation or
angiogenesis. An increase in apoptosis is apparently sufficient to
reduce the number of detectable adenomas. The apoptotic activity
of MMPs and of their endogenous inhibitors, TIMPs, is a
controversial subject. In some cases, MMPs have been shown to
be proapoptotic while in other cases they are implicated to be
antiapoptotic (for review see Egeblad and Werb, 2002; Jiang et al,
2002). These contradictory results may be partially explained by
the different cell and tissue systems under examination. In our
study, it is clear that chronic administration of an MMP inhibitor
results in increased apoptosis in intestinal adenomas supporting a
role for MMPs in the survival of benign intestinal epithelial cells.
The COX-2I also increased tumour cell apoptosis, consistent
with previous reports of proapoptotic effects of COX-2 inhibition
(Ballif et al, 1996; Chan et al, 1998; Hsu et al, 2000). The
combination of the MMPI and the COX-2I had no additional
statistically significant effect on the apoptotic index. This raises the
possibility that these compounds alter converging pathways that
affect tumour cell apoptosis. COX-2 has been shown to increase the
levels of MMP-2, -9, and -14, while NSAIDS and COX-2 inhibitors
have been reported to alter the levels of MMP-1, -2, -3, -9 (Ito et al,
1995; Takahashi et al, 1997, 1999; Attiga et al, 2000; McLaren et al,
2000; Callejas et al, 2001; Jiang et al, 2001). Recent reports have
shown that NSAIDs inhibit MMP expression and activation
through both COX-2-dependent and independent mechanisms
such as through modulation of gene transcription via the ERK/Sp1
signalling pathway or through induction of the membrane-
anchored MMP inhibitor RECK (Pan et al, 2001; Liu et al, 2002;
Pan and Hung, 2002). Thus, the COX-2 effect on apoptosis may be
mediated by alterations in MMP activity, explaining why there is
no additional proapoptotic benefit of inhibiting both pathways.
The COX-2I reduced adenoma proliferation as determined by
Ki67 staining. Several studies have shown prostaglandins to be
important modulators of cell proliferation (Sheng et al, 1997;
Castano et al, 2000). More recently, expression of COX-2 has been
shown to be cell cycle dependent in human fibroblasts (Gilroy et al,
2001) and associated with G1 delay in intestinal epithelial cells
(DuBois et al, 1996). Even earlier than cell growth, COX-2
inhibitors block carcinogenesis in animal models (Prescott and
Fitzpatrick, 2000), and recently the Hla laboratory has shown that
overexpression of COX-2 in mice was sufficient to cause
tumorigenicity (Liu et al, 2001). Older nonselective agents and
more recently new selective COX-2 inhibitors have been shown to
have anticancer effects in animal models and some human
tumours (Fosslien, 2000). Thus, the proapoptotic and antiproli-
ferative effects of COX-2 inhibition presented here are consistent
with observations in other models.
The most interesting observation of these studies is the effect of
the MMPI and COX-2I on tumour-associated angiogenesis. Neither
compound significantly altered angiogenesis alone at the doses
given, but the combination resulted in a 53% reduction in VWF-
stained blood vessels. Previous studies have indicated that both
COX-2 and MMP inhibition have antiangiogenic effects (Jones et al,
1999; Stetler-Stevenson, 1999; Williams et al, 2000). Thus, it is
possible that higher doses of either compound would have shown
significant alteration in VWF-stained blood vessels, implying that
a critical threshold must be reached to observe inhibition of
angiogenesis. The combination of low doses of both agents may
have acted in an additive fashion and been sufficient to cross this
threshold. Alternatively, the MMPI and COX-2I may have acted on
different pathways in a synergistic manner to affect angiogenesis.
Additional dose–response studies would be required to distin-
guish between these two possibilities. It is unclear if the target in
this case is the tumour epithelium or endothelium. Enzymes
produced in tumour epithelium may be involved in stimulating
pathways that release angiogenic factors. Alternatively, MMPs or
COX-2 produced by endothelial cells may be essential for their
growth, viability, or ability to make new blood vessels. Both MMPs
and COX-2 are expressed in tumour-associated endothelial cells
and inhibition of these enzymes could stimulate the cells to
undergo apoptosis. The COX-2 inhibitor Celecoxib has been
previously been shown to induce apoptosis in endothelial cells
(Leahy et al, 2002). TUNEL analysis of tumour sections show that
the majority of the apoptosis occurs in the epithelial component of
the tumour; however, some TUNEL-positive cells can be seen
within the stromal component and may be endothelial cells
(Figure 2). In preliminary studies, we have observed a cooperativity
between low doses of the MMPI and COX-2I in inducing apoptosis
in cultured endothelial cells (data not shown). Thus, the target of
the inhibitors may be both tumour epithelium and endothelium.
MMP inhibitors have been successfully used in preclinical
models to demonstrate that MMPs are important in several
different tumour types (Nelson et al, 2000). In general, the results
of Phase III clinical trials in advanced stage cancers have been
disappointing, although the broad-spectrum MMPI marimastat
showed some efficacy in patients with gastric cancer (Fielding et al,
2000). Several reasons for the clinical failure of MMPIs have been
proposed, including the inappropriate testing in advanced-stage
disease settings (Coussens et al, 2002). The ability to detect
premalignant disease and the progressive nature of colorectal
cancer makes it amenable to treatment at early stages, and provides
a model for testing of novel preventive strategies. MMPIs, like
COX-2Is, are ideal candidates for chemoprevention agents in trials
with patients with recurring polyps (Marnett and DuBois, 2002).
Treatment with two different inhibitors with independent
signalling pathways may decrease the toxicity of drugs by reducing
the dose necessary to achieve the same effect. Recent findings
(Torrance et al, 2000) demonstrate that combination treatment of
Min mice with NSAIDs and EGF receptor kinase inhibitors
cooperate to inhibit tumour multiplicity. Additionally, the
combination of an MMP inhibitor with a COX-2 inhibitor may
be used with traditional cytotoxic agents, based on promising
results observed with such agents used in combination with either
a MMP or COX-2 inhibitor (Neri et al, 1998; Fosslien, 2000). These
data together with our data suggest that a combination of agents
may be effective in the prevention of colon cancer. These findings
are significant in that they represent potential chemopreventative
targets for treatment or may be a more easily tolerated
chemotherapeutic treatment for colon cancer.
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